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Abstract
Single nucleotide polymorphisms (SNPs) are extensively used in case-control studies of practically
all cancer types. They are used for the identification of inherited cancer susceptibility genes and
those that may interact with environmental factors. However, being genetic markers, they are
applicable only on heritable conditions, which is often a neglected fact. Based on the data in the
nationwide Swedish Family-Cancer Database, we review familial risks for all main cancers and
discuss the evidence for a heritable component in cancer. The available evidence is not conclusive
but it is consistent in pointing to a minor heritable etiology in cancer, which will hamper the success
of SNP-based association studies. Empirical familial risks should be used as guidance for the planning
of SNP studies. We provide calculations for the assessment of familial risks for assumed allele
frequencies and gene effects (odds ratios) for different modes of inheritance. Based on these data,
we discuss the gene effects that could account for the unexplained proportion of familial breast and
lung cancer. As a conclusion, we are concerned about the indiscriminate use of a genetic tool to
cancers, which are mainly environmental in origin. We consider the likelihood of a successful
application of SNPs in gene-environment studies small, unless established environmental risk
factors are tested on proven candidate genes.
Introduction
Genetic association studies on complex diseases have
become very popular and most of them are case-control
studies using single nucleotide polymorphisms (SNPs) as
markers. There has been concern about the poor repro-
ducibility of the results and the reasons for such discrep-
ancies have been discussed [1-5]. However, the theoretical
underpinnings of such studies have attracted less atten-
tion, apart from the use of SNPs as mapping tools, an
application which we will not discuss in the present article
[6-8]. Heritable etiology in many common diseases may
not be overwhelming, and the use of genetic tools to dis-
sect disease causation may thus be questionable. For can-
cer, all useful etiological measures, such as incidence
changes upon time and migration, and aggregation of
cancer among twins and families, point to a predominant
environmental contribution to cancer causation [9-15].
However, in these contexts, the environment is anything
that is not inherited, including variables that can be meas-
ured in epidemiological studies, in addition to un-meas-
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urable and random, stochastic events. The fact that only a
minority of smokers are diagnosed with lung cancer is
often cited as evidence for inherited differences in suscep-
tibility to tobacco carcinogenesis. There are also other
possible reasons, such as time-dependent stochastic
effects, which in inbred animals are the likely reason that
only some animals develop cancer when exposed to a
constant level of a carcinogen.
How feasible is it then to carry out SNP studies on cancer,
particularly when the subjects are overwhelmingly unse-
lected cases, among whom familial cases are rare. It is wor-
risome that genotyping is now almost a required standard
component in epidemiological studies, without consider-
ation of the expected heritable influence. Formal sample
size and power calculations are irrelevant if there are no
data on the assumed heritable component in the causa-
tion of a particular cancer. It is also worrisome that the
fundamental differences between purely genetic and gene-
environment studies regarding control populations and
multiple testing problems are not appreciated. In this con-
tribution, we first review study designs and aims of SNP
studies, then we give data on familial risks for the main
types of cancer, to give an idea of the upper bounds for the
risks that can be expected in genotyping studies. Finally,
we will calculate familial risks resulting from variants of
assumed genotype relative risk and allele frequency. Such
data are useful in the assessment of study designs and in
the evaluation of obtained results. We use the term 'famil-
ial' to denote cancers in two or more first-degree relatives
and 'heritable' when an inherited gene defect is known or
inferred due to a high risk [16]. Instead of 'genotype rela-
tive risk', we refer to 'odds ratio' (OR), consistent with ter-
minology of most association studies.
Study designs and aims
In the simplest form, a SNP with a known or assumed
function is selected, and the genotypes are determined in
cases and controls to test for association. Most studies
published on cancer are of this kind, purely "genetic stud-
ies" testing the effect of the genotypes on the risk of can-
cer, without considering any other variables [17,18]. In
addition to genotype effects, some studies have incorpo-
rated the effects of haplotypes and data on functional
effects of the studied SNPs [19-21]. Population stratifica-
tion has been an issue in association studies and it is
important that the control subjects are drawn from the
same ethnic and geographic population [2,5]. However,
there is no need for individually based matching (age,
gender etc.), typical of epidemiological case-control stud-
ies, as long as the genotypes of the control population fol-
low the Hardy-Weinberg equilibrium [22,23]. Multiple
testing is an issue in "genetic studies" but solutions are
available, for example using the Bonferroni adjustment
[2,5].
Most studies have selected SNPs with assumed functional
effects or they test the effects of haplotypes. For some
genes, null or truncating alleles exist and homozygotes
would then lack a functional protein. However, for mis-
sense types of SNPs the functional effects may be small or
nil when tested in in vivo systems [21]. Unfortunately, for
many genes an in vivo functional test cannot be easily
devised. Drug metabolism genes are a fortunate exception
in this regard, because aberrant responses in humans have
lead to the characterization of the underlying gene vari-
ants. One common feature of almost all the published
studies is that patients have been collected without regard
of a family history, thus sacrificing statistical power but
attempting to compensate with a large sample size
[24,25]. Using familial cases would be advantageous sta-
tistically, and some effects, such as that of
CHEK2*1100delC, have only been detected among famil-
ial cases [26].
A variant of the candidate gene approach is the "gene-
environment study", which is founded on the assumption
that in complex diseases environmental factors interact
with heritable factors, and a strong effect can be detected
when both are present [27-29]. In epidemiology, interac-
tions (also called effect modifications) are best described
for multiple exposures, which may be additive, multipli-
cative or mixed [30]; these probably also apply to gene-
environment interactions, but there are few bonefied
examples on quantified gene-environment interactions
[29]. It is conceptually appealing to assume that environ-
mental factors interact with the genetic make-up to cause
a differential susceptibility to cancer. However, examples
are needed in order to verify this concept and its magni-
tude in cancer causation. The SNP component has
become a favored adjunct to epidemiological studies, pro-
moted with the hypothesis that the small, perhaps insig-
nificant effects noted between exposure and cancer can be
salvaged by incorporation genetic host factors into the
study. These studies always include multiple compari-
sons, firstly, including the epidemiological variables in
various classes, which may add up to thousands of cells (a
small study with 5 variables in 5 strata each results in 55 =
3125 unique cells), and, secondly, the genes that are
selected for analysis, are taken from a pool of tens or hun-
dreds of potential candidate genes. No solutions have
been found for this "two-dimensional" multiple testing
problem. However, important for the present discussion,
gene-environment interactions only exist if there is a her-
itable component in the particular cancer, and the likeli-
hood of observing an effect is larger if the heritable
component is large.
In populations of random mating, it may be plausible that
gene-environment interactions of epidemiologically
measurable magnitude exit in the absence of a measurableJournal of Carcinogenesis 2005, 4:2 http://www.carcinogenesis.com/content/4/1/2
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familial risk. In the case of many exposures, some with
harmful and others with protective effects, interacting
with many genes, it may be possible that the familial risks
are missed in spite of true gene-environment effects. Sim-
ilarly, non-conventional dose-effect relationships, such as
those suggested for blood vitamin D levels and prostate
cancer [31], would be difficult to reconcile in terms of any
genetic models.
According to the complex disease paradigm, many rela-
tively common alleles, interacting with environmental
factors, cause susceptibility to common diseases [28,32].
Such a "non-Mendelian" inheritance may not cause an
appreciable familial risk because the penetrance is so low
that the likelihood of several family members being
affected would be small. Twin studies should be able to
assess the contribution of polygenic heritability [33], and
the heritability estimates derived for colorectal (35% her-
itability), breast (27%) and prostate (42%) cancers, the
only significant ones among site-specific cancers, encom-
pass the total (broad) heritability, as definable using the
twin model [11]. The much smaller heritability estimates,
generated from family studies, were thought to result in
part because of inability to consider such polygenic effects
[13].
Familial risks and proportions
Familial risk of a disease is a measure of its clustering in
family members. Commonly, familial risk is defined
between those who have a relative (e.g., parent or sibling)
with cancer compared to those whose relatives are free
from cancer, given as a familial relative risk or familial
standardized incidence ratio (SIR). The SIRs shown below
have been obtained from the Swedish Family-Cancer
Database, the largest dataset of the kind in the world [34].
Familial SIRs have been adjusted for age, socio-economic
status, period and region, and for women, for reproduc-
tive parameters. Table 1 shows familial SIRs for 0 to 68
year old offspring whose parents had the same cancer
[35]. Table 1 also shows the number of observed cases,
95% confidence intervals (95%CIs) for the SIRs and the
familial proportions, i.e., the percentage of all affected off-
spring who have an affected parent. A total of 4938 con-
cordant familial cancers were found, with an overall SIR of
2.02. All the site-specific familial risks were significantly
increased, except those for connective tissue. Hodgkin's
Table 1: SIR for cancer in offspring by parental concordant cancer
Cancer site O SIR 95%CI Familial proportion, %
Breast 1779 1.84 1.76 1.93 8.5
Prostate 922 2.45 2.29 2.61 15.4
Colorectum (adenocarcinoma) 681 1.86 1.73 2.01 10.1
Lung 365 2.09 1.88 2.32 6.6
Melanoma 166 2.62 2.23 3.05 2.5
Urinary bladder 117 1.75 1.45 2.10 3.9
Nervous system 112 1.75 1.44 2.11 1.8
Ovary 97 3.15 2.56 3.85 3.3
Endometrium 83 2.47 1.97 3.07 2.9
Stomach 82 2.17 1.72 2.69 5.5
Skin, squamous cell 77 2.52 1.99 3.15 4.1
Non-Hodgkin's lymphoma 74 1.82 1.43 2.29 2.1
Kidney 64 1.87 1.44 2.39 2.8
Leukemia 55 1.88 1.42 2.45 1.7
Pancreas 46 1.87 1.37 2.49 3.0
Upper aerodigestive tract 39 1.71 1.22 2.35 1.9
Cervix 39 1.82 1.29 2.49 1.7
Endocrine glands 38 2.22 1.57 3.06 1.5
Liver 37 1.66 1.17 2.28 2.6
Myeloma 23 3.32 2.10 5.00 2.6
Thyroid gland, nonmedullary 12 3.26 1.68 5.71 1.0
Testis 10 4.35 2.07 8.04 0.5
Esophagus 8 3.14 1.34 6.22 1.3
Hodgkin's disease 8 4.91 2.10 9.73 0.7
Connective tissue 4 1.87 0.49 4.84 0.5
All 4938 2.02 1.97 2.08 5.5
Bold type: 95%CI does not include 1.00.
Familial proportion: % of affected offspring with affected parentJournal of Carcinogenesis 2005, 4:2 http://www.carcinogenesis.com/content/4/1/2
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disease showed the highest SIRs of 4.91, followed by tes-
ticular (4.35) and non-medullary thyroid cancers (3.26).
Esophageal and ovarian cancers and multiple myeloma
had SIRs in excess of 3.00. Among common cancers, the
SIRs were increased for female breast (1.84), prostate
(2.45) and colorectal adenocarcinoma (1.86), and the
number of familial pairs ranged between 681 and 1779
for these common cancers. Apart from colorectal, breast
and ovarian cancer, hardly anything is known about the
genetic bases of these neoplasms, which should be good
news to those who want to test the effects of candidate
genes [36,37].
Familial cases constituted 15.4% of all prostate cancers,
which was the largest proportion by far. The proportion
was 10.1% for colorectal adenocarcinoma and 8.5% for
breast cancer, but only 0.5% for connective tissue and tes-
ticular tumors. The proportions are generally higher for
common cancers. Overall familial cancers (same cancer in
offspring and parents) constituted 5.5% of all cancers.
We have tried to estimate the degree of environmental
contribution to the familial risk by comparing cancer risks
betweens spouses. Spouse concordance, which does not
generally exceed an SIR of 1.3, can be noted only for can-
cers with known strong environmental risk factors: lung
and genital cancers and early onset gastric and pancreatic
cancers and melanoma [38,39]. Spouse correlation does
not consider environmental sharing early in the life; this
has been estimated by comparing cancer risks between
siblings with a small or large age difference, respectively
[40]. For most sites, including the breast and the colorec-
tum, heritability is likely to be the main contributor to
familial cancer [41,42]. Environmental factors are proba-
bly a large contributor to the familial aggregation of cervi-
cal, lung and upper aerodigestive tract cancers, and a
minor contributor to familial risks for melanoma and
squamous cell skin cancer [43,44].
If environmental causes of familial clustering have been
quantified or excluded, familial SIRs and proportions give
estimates on the heritable effects for cancer at the level of
nuclear families (here between parents and offspring).
Because of low penetrance, familial proportions underes-
timate true heritable effects. On the other hand, the twin
model assumes that the shared environmental effects of
monozygotic and dizygotic twins are identical, which may
not be true. If monozygotic twins share more than dizy-
gotic twins, the estimated heritability is exaggerated. Thus,
the heritability estimates for cancer are still unreliable,
and, due to possible interactions, a dichotomous classifi-
cation into heritable and environmental components is
conceptually inaccurate [45]. Moreover, the current mod-
els for twin studies do not allow the existence of interac-
tions, a condition probably violated for many cancers.
Nevertheless, the available data suggest that the heritabil-
ity is low for most cancers, and even for prostate, breast
and colorectal cancer it contributes a small etiological
proportion.
Familial risks from snps
Results from a successful SNP study can imply that the
particular variant contributes to a familial risk of the par-
ticular cancer. The resulting familial risk depends on the
allele frequency of the SNP, observed OR and the mode of
inheritance, i.e., on the relative risks of heterozygotes
compared to homozygotes. In the dominant model, the
risk of heterozygotes equals that of the variant homozy-
gotes; in the recessive model, the risk of heterozygotes
equals that of the wild type homozygotes. In the additive
model, the risk of heterozygotes is the mean of the two
homozygotes; in the multiplicative model, the risks
between the genotypes differ by a constant multiplier.
The methods for the calculation of familial risks to off-
spring of affected parents (comparable to SIRs of Table 1),
based on allele frequency and OR of the genotype are pre-
sented elsewhere [46]. According to Table 2, the calcu-
lated familial risk is negligible at very low and very high
allele frequencies when ORs are below 10, and at any
allele frequency when OR is 2 or less. Most SNP studies
are carried out on variants with frequencies at 5% or
higher, and then substantial familial risks may be caused
by a single gene with a high OR. Familial risk of breast
cancer was 1.84 in Table 1; however, because the known
genes, including BRCA1/2, ATM, p53 and CHEK2, explain
about 25% of the risk [47], the unexplained familial risk
is about 1.6. In Table 2 we have fold-faced SIRs that are
incompatible with the empirical data for breast cancer
(risk 1.60 or more), i.e., the resulting familial SIRs would
be too high. If a single dominant gene would explain all
the remaining familial risk of breast cancer, the allele fre-
quency should be 0.2 and OR about 15; with allele fre-
quency of 0.01, OR should be about 10. In the more likely
scenario, many genes contribute to the familial risk, but
their joint effect cannot exceed the above values.
Because the prevalence has no effect on the calculated
familial risks, Table 2 can be used for any cancers of vari-
able prevalences. The familial SIR for lung cancer was 2.09
(Table 1). However, judged from the spouse correlation,
probably a large but undefined proportion of familial risk
for lung cancer can be explained by environmental fac-
tors, and the unexplained heritable component may be
not very different from breast cancer. For upper aerodiges-
tive tract cancers, the familial SIR was 1.71, but tobacco
smoking and other environmental factors probably con-
tribute to familial clustering and the heritable component
is likely to be relatively small in this cancer.Journal of Carcinogenesis 2005, 4:2 http://www.carcinogenesis.com/content/4/1/2
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It is of interest to examine the magnitude of familial risks
which would be predicted from the published ORs for
candidate genes. In a review of 34 polymorphisms in 18
different genes tested for breast cancer, a large proportion
of the associations were not significant and the ORs were
below 2.0 [17]. Even many significant ORs were below 2.0
and the resulting familial risk is negligible. However, there
were some exceptions; in one study, TNF-alpha with an
allele frequency of 0.2 showed an additive risk of about 10
(homozygote/homozygote). According to Table 2, the
resulting familial risk would be about 1.4, i.e., if the effect
were true, this gene would explain half of all familial risk
for breast cancer; in that respect it would be two times
more important than BRCA1 and BRCA2 combined. The
effects of metabolic polymorphisms on various cancers
have been reviewed in an IARC publication [48]. Among
many genes, CYP2D6 has been analyzed in many studies
as a risk factor for lung cancer, although it is not expressed
in lung tissue [49,50]. Some genotyping studies have
reported ORs between 5 and 15 for poor metabolizer gen-
otypes. Assuming an allele frequency of 0.02 and a domi-
nant OR of 10, Table 2 gives a familial risk of about 1.8,
which, if true, would account for all familial risk of lung
cancer not explainable by environmental factors.
Conclusions
The poor reproducibility of candidate gene studies has
most commonly been associated to small sample size,
population stratification and low prior probability, i.e.,
poor selection of genes or SNPs; a SNP with small func-
tional effect would also imply a low prior probability for
an effect [5,32]. We agree that the low prior probability is
an important factor but we would like to widen the scope
of the query from the right gene to the right tool: is the
genomic tool generally applicable to a disease that is
mainly environmental? It is likely that some successes will
continue to come in associating new genes with cancers of
a reasonable heritable component, such as that of
CHEK2*1100delC in breast cancer, and populations of
familial cancers will be important either in finding the ini-
tial association or in confirming the effect. In spite of the
unsolved multiple testing problems, we consider plausi-
ble that gene-environment interactions will be established
between demonstrated risk factors and proven candidate
genes, for which tobacco-induced lung cancer would
appear an obvious choice; however, even the candidate
genes for lung cancer are still being searched. Testing of
unproven genes and/or unproven environmental factors
for gene-environment interactions is the high-risk design
for a multiple testing outcome. It is worrisome to the field
of gene-environment interactions that no such proof-of-
principle has yet been demonstrated.
It is commendable that all available molecular and envi-
ronmental data are being used in attempts to understand
the mechanisms of human cancer [51-53]. With increas-
ing understanding of the cellular mechanisms more useful
tools will become available. Even though these cellular
systems are governed by heritable genes, variants in these
genes may not have an impact large enough to predispose
to heritable cancer. With current technological resources
there is a growing danger that technology rather than biol-
ogy is becoming the driving force in population studies
[3]. Although the new technologies will allow benefits for
the analysis of multiple SNPs and haplotypes in genetic
pathways rather than in individual genes, they will not
Table 2: Familial risk to offspring of affected parents assuming 
define allele frequencies and their effects according various 
genetic models
OR
Allele frequency 1.5 2 5 10 20
Dominant model
0.001 1.00 1.00 1.02 1.08 1.33
0.01 1.00 1.01 1.13 1.57 2.84
0.05 1.01 1.04 1.36 1.99 2.90
0.1 1.02 1.05 1.38 1.80 2.24
0.2 1.02 1.06 1.28 1.46 1.60
0.3 1.02 1.05 1.18 1.27 1.33
0.4 1.01 1.03 1.11 1.15 1.18
0.5 1.01 1.02 1.06 1.08 1.10
Additive model
0.001 1.00 1.00 1.00 1.02 1.09
0.01 1.00 1.00 1.04 1.17 1.63
0.05 1.00 1.01 1.13 1.46 2.13
0.1 1.01 1.02 1.18 1.50 1.97
0.2 1.01 1.03 1.20 1.41 1.63
0.3 1.01 1.03 1.17 1.31 1.42
0.4 1.01 1.03 1.14 1.23 1.29
0.5 1.01 1.03 1.11 1.17 1.20
Recessive model
0.001 1.00 1.00 1.00 1.00 1.00
0.01 1.00 1.00 1.00 1.00 1.00
0.05 1.00 1.00 1.00 1.01 1.04
0.1 1.00 1.00 1.01 1.06 1.23
0.2 1.00 1.01 1.08 1.28 1.75
0.3 1.00 1.02 1.16 1.47 1.93
0.4 1.01 1.03 1.23 1.52 1.85
0.5 1.01 1.04 1.25 1.48 1.68
Multiplicative model
0.001 1.00 1.00 1.00 1.00 1.01
0.01 1.00 1.00 1.01 1.04 1.11
0.05 1.00 1.01 1.06 1.18 1.42
0.1 1.00 1.01 1.11 1.28 1.60
0.2 1.01 1.02 1.16 1.36 1.67
0.3 1.01 1.03 1.17 1.36 1.61
0.4 1.01 1.03 1.16 1.32 1.51
0.5 1.01 1.03 1.15 1.27 1.40Journal of Carcinogenesis 2005, 4:2 http://www.carcinogenesis.com/content/4/1/2
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change the fact that cancer is mainly an environmental
disease, expressed as somatic alterations on a heritable
background. Forcing unproven genetic paradigms into all
epidemiological studies is risky, and the likelihood of
contradictory results may increase, leading to a gradual
erosion of credibility.
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